Drug design, development and therapy · 2025
The Effects of Different Ciprofol Doses on Hemodynamics During Anesthesia Induction in Patients Undergoing Cardiac Surgery: A Randomized, Double-Blind, Controlled Study.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Yingting, Liu ZiYou, Li QianQian, Ni PengFei, Li ZuoHui, Yu BeiJia, Zhang Min, Yang Jia, Xie YanHu
Аннотация
OBJECTIVE: To evaluate the effects of different ciprofol doses on hemodynamics in patients undergoing cardiac surgery.
METHODS: 209 patients were randomly divided into four groups: 0.2 mg/kg etomidate group (group E, n = 50), 0.2 mg/kg, 0.3mg/kg, 0.4mg/kg ciprofol group (group A, n = 53, group B, n = 51, group C, n = 54). Mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and bispectral index were recorded at the following time points: 5 minutes after entering the operating room (T0); before anesthesia induction (T1); immediately after induction (T2); 1 minute and 2 minutes after induction (T3~T4); at intubation (T5); 1 minute, 3 minutes, 5 minutes and 10 minutes after intubation (T6~T9); at skin incision (T10). The incidence of hypotension and bradycardia and the doses of vasoactive drugs were recorded.
RESULTS: Compared with T0, HR, MAP, SV, CO all decreased to varying degrees after administration, and the decrease time in Group B and Group C were earlier than that in other two groups (P < 0.05). SVR increased slowly after T4 in all groups, but there was no significant differences (P > 0.05). Compared with group E, the norepinephrine dose was significantly lower in groups A and B (both P < 0.05). Group C showed a greater decline in CO and SV than the other three groups from T7 to T10 (P < 0.05), while there was no significant difference between groups A and E in CO and groups A, B, and E in SV (P > 0.05). No significant differences were observed in MAP, SVR, and the incidences of hypotension and bradycardia among the four groups (P > 0.05).
CONCLUSION: 0.2 mg/kg ciprofol has the least impact on hemodynamics in patients undergoing cardiac surgery, and reduced norepinephrine use.
METHODS: 209 patients were randomly divided into four groups: 0.2 mg/kg etomidate group (group E, n = 50), 0.2 mg/kg, 0.3mg/kg, 0.4mg/kg ciprofol group (group A, n = 53, group B, n = 51, group C, n = 54). Mean arterial pressure (MAP), heart rate (HR), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and bispectral index were recorded at the following time points: 5 minutes after entering the operating room (T0); before anesthesia induction (T1); immediately after induction (T2); 1 minute and 2 minutes after induction (T3~T4); at intubation (T5); 1 minute, 3 minutes, 5 minutes and 10 minutes after intubation (T6~T9); at skin incision (T10). The incidence of hypotension and bradycardia and the doses of vasoactive drugs were recorded.
RESULTS: Compared with T0, HR, MAP, SV, CO all decreased to varying degrees after administration, and the decrease time in Group B and Group C were earlier than that in other two groups (P < 0.05). SVR increased slowly after T4 in all groups, but there was no significant differences (P > 0.05). Compared with group E, the norepinephrine dose was significantly lower in groups A and B (both P < 0.05). Group C showed a greater decline in CO and SV than the other three groups from T7 to T10 (P < 0.05), while there was no significant difference between groups A and E in CO and groups A, B, and E in SV (P > 0.05). No significant differences were observed in MAP, SVR, and the incidences of hypotension and bradycardia among the four groups (P > 0.05).
CONCLUSION: 0.2 mg/kg ciprofol has the least impact on hemodynamics in patients undergoing cardiac surgery, and reduced norepinephrine use.